Once daily versus twice daily enoxaparin for acute pulmonary embolism in cancer patients

Conclusion Cancer patients receiving once daily enoxaparin for the treatment of acute PE may be at increased risk of recurrent PE and clinically overt bleeding. Larger randomized trials are needed to confirm the results of this study.
Source: Journal of Oncology Pharmacy Practice - Category: Cancer & Oncology Authors: Tags: Original Articles Source Type: research